CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 90 filers reported holding CATALYST PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 1.06 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $195,000 | -4.9% | 42,117 | -20.7% | 0.11% | -17.8% |
| Q1 2020 | $205,000 | -6.4% | 53,117 | -8.9% | 0.13% | +44.9% |
| Q4 2019 | $219,000 | -72.8% | 58,317 | -61.5% | 0.09% | -73.7% |
| Q3 2019 | $804,000 | -39.0% | 151,415 | -55.9% | 0.34% | -39.2% |
| Q2 2019 | $1,318,000 | -49.4% | 343,347 | -32.8% | 0.56% | -46.4% |
| Q1 2019 | $2,605,000 | +121.1% | 510,847 | -16.7% | 1.04% | +87.4% |
| Q4 2018 | $1,178,000 | -43.7% | 613,447 | +10.8% | 0.55% | -18.4% |
| Q3 2018 | $2,092,000 | +30.6% | 553,475 | +7.8% | 0.68% | +13.0% |
| Q2 2018 | $1,602,000 | +37.2% | 513,475 | +5.1% | 0.60% | +24.9% |
| Q1 2018 | $1,168,000 | -21.4% | 488,575 | +28.5% | 0.48% | -18.6% |
| Q4 2017 | $1,486,000 | +61.5% | 380,110 | +4.1% | 0.59% | +50.4% |
| Q3 2017 | $920,000 | -6.3% | 365,110 | +2.6% | 0.39% | -4.1% |
| Q2 2017 | $982,000 | +77.3% | 355,750 | +25.1% | 0.41% | +53.6% |
| Q1 2017 | $554,000 | – | 284,350 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $2,458 | 7.14% |
| GABLES CAPITAL MANAGEMENT INC. | 409,080 | $6,782,546 | 4.74% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,355,099 | $171,687,541 | 3.83% |
| JW Asset Management, LLC | 563,392 | $9,341,039 | 3.58% |
| Quantedge Capital Pte Ltd | 324,700 | $5,383,526 | 2.10% |
| Paradiem, LLC | 236,628 | $3,923,292 | 1.22% |
| SummerHaven Investment Management, LLC | 100,592 | $1,667,815 | 0.97% |
| Capital Impact Advisors, LLC | 46,096 | $764,272 | 0.94% |
| Yorktown Management & Research Co Inc | 50,000 | $829,000 | 0.89% |
| Seaport Global Advisors, LLC | 15,598 | $258,615 | 0.82% |